XPD (ERCC2) is a DNA helicase involved in nucleotide excision repair and in transcription as a structural bridge tying the transcription factor IIH (TFIIH) core with the cdk-activating kinase complex, which phosphorylates nuclear receptors. Mutations in XPD are associated with several different phenotypes, including trichothiodystrophy (TTD), with sulfur-deficient brittle hair, bone defects, and developmental abnormalities without skin cancer, xeroderma pigmentosum (XP), with pigmentary abnormalities and increased skin cancer, or XP/TTD with combined features, including skin cancer. We describe the varied clinical features and mutations in nine patients examined at the National Institutes of Health who were compound heterozygotes for XPD mutations but had different clinical phenotypes: four TTD, three XP, and two combined XP/TTD. We studied TFIIH-dependent transactivation by nuclear receptor for vitamin D (VDR) and thyroid in cells from these patients. The vitamin D stimulation ratio of CYP24 and osteopontin was associated with specific pairs of mutations (reduced in 5, elevated in 1) but not correlated with distinct clinical phenotypes. Thyroid receptor stimulation ratio for KLF9 was not significantly different from normal. XPD mutations frequently were associated with abnormal VDR stimulation in compound heterozygote patients with TTD, XP, or XP/TTD.
INTRODUCTION
Trichothiodystrophy (TTD) (MIM no. 601675) is a rare autosomal recessive multisystem disorder characterized by sulfur-deficient brittle hair, neurological abnormalities, ichthyosis, and cutaneous photosensitivity without skin cancer. 1 TTD may be manifested when both alleles are affected by mutations in one of the three DNA repair genes (XPB (ERCC3) MIM no. 133510, XPD (ERCC2) MIM no. 126340, TTDA (GTF2H5) MIM no. 608780), 2 or in TTDN1 (C7orf11) MIM no. 609188, 3 a gene of unknown function. Interestingly, mutations in XPB and XPD can also cause xeroderma pigmentosum (XP) (MIM no. 278730), [4] [5] [6] [7] with sunlight-induced freckle-like skin pigmentation and 410 000-fold increased risk of skin cancer. 8 TTD and XP have an incidence of about 1 per million live births in the United States and Western Europe. 9 Very rare XP/TTD patients have clinical features of both XP and TTD 10, 11 and carry an increased cancer risk.
The XPD, XPB, and TTDA proteins are associated with transcription factor IIH (TFIIH), a 10 protein complex involved in both initiation of transcription by RNA polymerase II and nucleotide excision repair. [12] [13] [14] [15] XP and TTD patients may have different, although overlapping, XPD mutations, suggesting that the site of mutation influences the clinical phenotype. 10, [16] [17] [18] [19] [20] Cells from XP and TTD patients with XPD mutations differ in the rate of repair of ultraviolet-induced DNA photoproducts and in the time course of localization and removal of nucleotide excision repair proteins to sites of UV damage. 10 Nuclear receptors are hormone-dependent transcription factors that play essential roles in development, differentiation, and metabolism by controlling the expression of specific networks of genes. 21, 22 XPD mutations reduce basal transcription activity in TTD cells and inhibit nuclear receptor transactivation in XP as well as in TTD cells. [23] [24] [25] Using our unique collection of fibroblast strains established from the TTD, XP, and XP/TTD patients we examined at the National Institutes of Health (NIH) over the past three decades, 8, [26] [27] [28] we selected cells from nine patients with XPD mutations (four TTD, two XP/TTD, and three XP), with varied and distinct clinical features. We tested two types of nuclear receptor, vitamin D receptor (VDR) and thyroid receptor, which are important for bone growth and maintenance, development, and innate and adaptive immunity. 21, 22 We hypothesized that these patients would have abnormal nuclear receptor transactivation.
of Helsinki Principles. Skin biopsies were obtained and sent to the Human Genetic Mutant Cell Repository (Camden, NJ, USA) or to NCI-Frederick (Frederick, MD, USA) for establishment of fibroblast cell cultures. Fibroblast cultures from four TTD, two XP/TTD, three XP patients (Table 1) , and normal controls AG04438 and AG13145 were grown in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) containing 4 mM glutamine and 10% fetal calf serum (FCS) (Hyclone Laboratories Inc., Logan, UT, USA) in an 8% CO 2 humidified incubator at 37 1C as described previously. 10 Mutation analysis was performed as described previously. 10 The XPD GenBank sequences used were NM_0000400.3 (XPD cDNA) with numbering based on þ 1 as the A of the ATG initiation codon and NP_000391.1 (XPD protein).
Hormone stimulation and DNA/RNA isolation Nuclear receptor activation was performed as described previously. 25 In brief, fibroblasts were plated at 50-60% confluence in complete media for 24 h. The media were changed to a phenol red-free media containing 10% charcoaltreated FCS and the cells were incubated for 12 h with either 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ; VD) (Sigma-Aldrich, St Louis, MO, USA) or triiodothyronine (T 3 ) (Sigma-Aldrich). Total cytoplasmic RNA was isolated from cells using the RNAqueous small-scale phenol-free total RNA isolation kit (Ambion Inc., Austin, TX, USA). DNA was isolated using DNAzol reagent (Invitrogen, Carlsbad, CA, USA).
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR (qPCR) was performed as described. 25 Total RNA was treated with DNA-free DNase (Ambion Inc., Austin, TX, USA) and then converted to cDNA using Superscript II (Invitrogen, Carlsbad, CA, USA) as described. 29 A measure of 2 ml (corresponding to 25 ng RNA) of RT reaction was used as template for each PCR reaction. qPCR assays were carried out on a Bio-Rad iCycler iQ system (Bio-Rad Laboratories Inc., Hercules, CA, USA) using intercalation of SYBR Green (iQ SYBR Green Supermix; Bio-Rad) as the fluorescence reporter. Two-step PCR (denaturation at 95 1C for 15 s and annealing/extension at 58 1C for 1 min) was performed with data collection and analysis during the combined annealing and extension step. Melt-curve analyses were performed on all PCR reactions to rule out nonspecific amplification. The following forward and reverse primer sequences were used for the target genes: CYP24 MIM no. 126065 (VD target gene) - 
Data analysis and statistics
The results are the mean of at least two independent experiments performed with duplicate samples. All data are presented as fold change against each control (specified as either mean of non-stimulated cells or mean of normal cells under the same conditions). Student's t-test with a two-tailed distribution was used to analyze the data. Statistical significance was judged to be a P-value of o0.05.
RESULTS
Clinical features differ markedly among TTD, XP, and XP/TTD patients with XPD mutations Patient TTD354BE was a Caucasian female with TTD (Figures 1a-c) who was compound heterozygous for a previously unreported XPD mutation (p.G459-T460ins34aa) and p.A725T, which was present in another TTD patient (TTD421BE) 30 (Table 1 and Figure 2 ). TTD354BE had features of severe TTD, 1,31 including tiger tail banding of her hair (Figure 1c ), short stature (o3%-ile), congenital cataracts, microcephaly, brain dysmyelination, global developmental delay, including central osteosclerosis and peripheral osteopenia of her bones, elevated hemoglobin A2 (HbA2) levels, and a low mean corpuscular volume. She had recurrent ear infections and pneumonias and died at the age of 9 years from acute infection following hip surgery. 27 Patient TTD412BE was a 7-year-old Caucasian male with TTD ( Figure 1d and e) 27 with p.A725P mutation in one XPD allele and p.L461V plus p.V716-R730del in the other allele, resulting from a g.18339C4G splice mutation (Table 1 and Figure 2 ). These same mutations have been reported previously in another patient (TTD183ME). 32 Interestingly, while TTD183ME was acutely sun sensitive, TTD412BE did not have this same sun sensitivity.
Patient TTD351BE (Table 1 and Figure 2 ) was a Caucasian male with a unique p.R378H mutation and the TTD-specific mutation, p.R722W. 20 A mouse engineered to have this mutation was shown to have some clinical features of TTD. 33 The TTD351BE cells had normal DNA repair. 10 The patient died at the age of 15 years owing to infection and respiratory failure following hip surgery. 27 Patient TTD404BE 27 was a 11-year-old Caucasian male with a novel p.R112C mutation at the same site as a more common p.R112H mutation reported in other TTD patients 11, 16 (Table 1 and Figure 2) . He also had a p.D681N mutation, which was present in a patient with cerebro-ocular-facial-skeletal (COFS) syndrome 34 and in XP patient XP17BE. 10 He had long hair with tiger tail banding under polarized microscopy.
Patient XPTTD268BE was a 25-year-old Caucasian male who had the commonly reported TTD mutation, p.R112H, and a unique p.C663R mutation 10 (Table 1 and Figure 2 ). He had long hair and TTD features of tiger tail banding on polarized microscopy, ichthyosis, cataracts, leukodystrophy, and recurrent infections. He also had XP-type freckle-like pigmentation supporting the diagnosis of XP/ TTD. 11 Patient XPTTD306BE was a 14-year-old Caucasian male with XP/ TTD who had a novel mutation, p.S51F, and a commonly reported TTD-specific mutation, p.R722W, in the XPD protein 10 (Table 1 and Figure 2 ). He had XP features of acute sun sensitivity and freckle-like skin pigmentation but no skin cancers. In addition, he had the characteristic TTD features of 'tiger tail' banding of his hair on polarized microscopy, ichthyosis, short stature, microcephaly, and brain dysmyelination and recurrent pneumonias. 6 Patient XP17BE 10 was an African-American male with the p.R683W mutation commonly seen in XP patients, 10, 17, 19, 20 as well as in XP29BE and XP34BE. He also had a p.D681N mutation, which was present in a COFS patient 34 and in a TTD patient TTD404BE (Table 1 and Figure 2) .
Patient XP29BE was a Caucasian male with severe XP phenotype with neurological abnormalities (Figure 1f ) who was compound heterozygous for p.R683W in one XPD allele and a premature stop codon p.Q452X mutation in the other allele 25, 35, 36 (Table 1 and Figure 2 ). Besides severe sunburning on minimal sun exposure, and extensive freckle-like pigmentation, he had 4300 skin cancers documented, including 24 cutaneous melanomas, 284 basal cell carcinomas, and 12 squamous cell carcinomas, despite treatment with oral retinoids. 35 He died at the age of 39 years owing to neurological degeneration.
Patient XP34BE was a Caucasian male with a mild XP phenotype (Figure 1g ) who had a p.R683W mutation from one XPD allele and a p.I199Pfs*52 mutation from the other allele, which arose from a splice Nuclear receptor transactivation in TTD and XP X Zhou et al Table 1 Clinical features and laboratory abnormalities of trichothiodystrophy (TTD) and xeroderma pigmentosum (XP) patients studied Nuclear receptor transactivation in TTD and XP X Zhou et al The XPD catalytic core of Sulfolobus acidocaldarius XPD (SaXPD) is comprised of four domains: two Rad51/RecA-like helicase domains (HD1 and HD2) with two additional domains (4FeS and Arch domains) inserted into HD1. 18 The helicase motifs (labeled with Roman numerals) are conserved from SaXPD to human XPD. 18 However, human XPD has an extended C-terminal domain (CTD) that has been proposed to be the TFIIH p44 interface. 23 The relative positions of the mutations found in XP patients (XP17BE, XP29BE, and XP34BE), TTD patients (TTD351BE,TTD354BE, TTD404BE, andTTD412BE), and XP/TTD patients (XPTTD268BE and XPTTD306BE) are shown. XP patient mutations are presented above the protein schematic, and TTD patient mutations and XP/TTD patient mutations are presented below.
Nuclear receptor transactivation in TTD and XP X Zhou et al mutation that gave rise to an insertion of eight nucleotides in the mRNA and a predicted truncated protein (Table 1 and Figure 2 ). He had a sister (XP35BE) who had the same mutations and a similar mild XP phenotype. 10, 25 He never developed skin tumors and had no evidence of neurological abnormalities by age 32 years. Eight of the nine patients had decreased DNA repair as measured by post-UV unscheduled DNA synthesis or post-UV fibroblast survival 10, 25 (Table 1 ). The only exception was patient TTD351BE.
Abnormal CYP24 induction in XPD mutant fibroblasts indicates abnormal transactivation of the VDR We analyzed by real-time quantitative RT-PCR the expression of two genes known to be under the control of VDR. One of these target genes, CYP24, encodes the cytochrome P450 enzyme vitamin D 3 hydroxylase that catalyzes the inactivation of vitamin D (VD). We used normal cells to determine the time and dose-response curves for CYP24 expression. The peak of CYP24 mRNA expression after vitamin D treatment was reached after about 12 h and then did not show a significant change, suggesting that it had reached the expression limit for that concentration of vitamin D (100 nM) (Figure 3a) . A similar time course was present in the TTD cells, although at lower peak levels (Supplementary Figure 1) . CYP24 expression increased with vitamin D concentration in a dosedependent manner (Supplementary Figure 2b) . The fold increase in CYP24 mRNA of treated relative to untreated control (induction ratio) was in the same range as that described previously for normal fibroblasts 39 (Figure 3a and Supplementary Figure 2a) . Given the strong CYP24 mRNA expression obtained from incubating the wild-type cells for 12 h with 100 nM vitamin D, we chose to use these same conditions for the patients' cells to allow comparison.
The response to vitamin D treatment varied with different cell lines and appears to be influenced by both alleles in these compound heterozygous patients. TTD cells TTD354BE, TTD412BE, TTD404BE, and XPTTD306BE had a significantly (Po0.05) reduced induction ratio when compared with the induction ratio of normal fibroblasts (B13 000-fold in AG04438 and B16 000-fold in AG13145) (Figure 3b) . XPTTD306BE had the greatest decrease, with only about a B300-fold induction ratio. By comparison, XP29BE and XP34BE had B3000-and B4000-fold induction ratios, respectively. This reduction is in accord with a previous study of CYP24 mRNA expression. 25 Of note, TTD404BE and XP17BE both have the same D681N allele and both have reduced CYP24 induction ratios. Interestingly, these same six TTD, XP/TTD, and XP cell strains also had elevated relative CYP24 baseline levels compared with the normal control (Supplementary Figure 2c, lower panel) . In contrast, the TTD and XPTTD cells (TTD351BE, XPTTD306BE) with the same p.R722W mutation in one allele (Figure 2 ) had opposite responses (Figure 3b and Supplementary Figure 2c) . TTD351BE, with an elevated CYP24 response, is the only TTD cell line with normal DNA repair (Table 1 and Boyle et al 10 ). In accord with previous studies, 25 these results suggest that the second mutated allele (R378H in TTD351BE and S51F in XPTTD306BE) may also influence the response. Also in agreement with the earlier study, 25 XP cells XP17BE, XP29BE, and XP34BE have the same R683W mutation, but differ in their responses to vitamin D (Figure 3b and Supplementary Figure 2c) and have different second mutated alleles. Nuclear receptor transactivation in TTD and XP X Zhou et al Abnormalities in OPN induction in XPD mutant fibroblasts further indicate mutation-dependent aberrant transactivation of the VDR To see whether this effect also involves other VDR target genes, we measured mRNA expression of the OPN gene. Osteopontin is implicated in a variety of physiological functions, including bone remodeling, 40 neutrophil chemotaxis, 41 and immune regulation. 42 OPN expression in normal cells increased with vitamin D concentration in a time-dependent manner (Figure 3c ) and in a dose-dependent manner (Supplementary Figure 3b) . Similar to our CYP24 data (Figure 3b) , we found that the greatest reduction in OPN induction ratio of treated to untreated cells was in TTD354BE and TTD412BE cells and, to a lesser extent, in XP17BE cells (Figure 3d and Supplementary Figure 3c ). Considering these similarities of the abnormalities in CYP24 and OPN expression, the data suggest that VDR transactivation may be less responsive to vitamin D stimulation in some of the XPD mutant cells.
We examined ICAM1, a gene that is not known to be responsive to VD, as a negative control. There was no significant increase in the ratio of expression of ICAM1 following VD treatment as compared with untreated cells in normal, or XPD mutant TTD or XP cells (Supplementary Figure 4) . KLF9 expression in XPD mutant fibroblasts TTD patients often have developmental neurological abnormalities such as microcephaly and brain dysmyelination, 1 whereas XP patients may have progressive neurological degeneration. 4, 7, 8 The thyroid hormone receptor has been shown to be crucial in normal brain development. 43 We measured the expression of KLF9 (also known as BTEB), a thyroid receptor-responsive gene in the fibroblasts. 25, 44 The normal cells had a time-and dose-dependent ( Supplementary Figures  5a and b) induction of KLF9 by treatment with triiodothyronine (T 3 ). The peak of KLF9 mRNA induction ratio in normal cells after treatment was reached after about 6 h. However, the relative amount of KLF9 mRNA expression from cells with or without T 3 treatment increased over time through 72 h. KLF9 induction ratio of treated cells over untreated cells was slightly reduced in TTD354BE, TTD412BE, XPTTD306BE and XP29BE, when compared with normal cells, but these results were not statistically significant ( Supplementary  Figure 5c) .
DISCUSSION
From the group of patients we examined at NIH, 8 we selected TTD, XP, and XP/TTD patients with XPD mutations who had markedly different clinical features (Table 1) . These patients all were compound heterozygotes for XPD mutations but shared some of the same mutations (Table 1 and Figure 2 ). TFIIH phosphorylation of nuclear receptors or their co-activated partners (such as Ets1 for VDR) is absent in certain XPD mutants (e.g., p.R683W mutants) 24, 45 and intracellular TFIIH concentration is reduced in TTD fibroblasts. 10, 16, 23 XPD is a structural bridge between the CAK complex (consisting of cdk7, cycH, and Mat1) and the TFIIH core, which together regulates RNA polymerase II function by phosphorylating its C-terminal domain. This step controls the transition from transcription initiation to elongation. 24, 46, 47 Thus, abnormalities in activation of nuclear receptor may be involved in some of the clinical features in these patients.
Ueda et al 25 demonstrated that each XPD allele contributes to the CYP24 response. While it is not possible to make unambiguous conclusions from non-isogenic human cell strains, this effect might be mutation dependent and be related to both XPD alleles. TTD351BE and XPTTD306BE cells both had p.R722W mutations, but the ratio of vitamin D stimulated to basal CYP24 expression was elevated in TTD351BE cells, but reduced in XPTTD306BE cells compared with the normal controls (Figure 3b ). The second allele in each cell line (p.R378H and p.S51F, respectively) thus might contribute to this differential response. Similar second allele mutation dependency could be evident in the three XP cell lines with p.R683W mutations. This is in agreement with an earlier study 25 that reported separate activities of each allele in XP29BE and XP34BE cells. Interestingly, cells with the p.R683W mutation also had a poor response to retinoid receptor stimulation, 24 and patient XP29BE, with this mutation, had a poor response to oral retinoid therapy for the prevention of skin cancers despite typical retinoid-related toxicities. 35 As reported previously, 25 there was no significant reduction in the OPN induction ratios for the XP29BE and XP34BE cells compared with normal cells. However, XP17BE cells and three of the TTD cell strains (TTD354BE, TTD412BE, and TTD351BE) had reduced OPN induction ratios compared with the normal controls (Figure 3d) . The results for KLF9, the response gene for the thyroid hormone receptor, were similar, although the magnitude of change was much smaller and would require a larger sample size to elucidate.
We did not observe a correlation between the nuclear receptor transactivation abnormalities and the different clinical phenotypes. This may be related to the fact that we were only able to study skin fibroblasts from our patients after birth. These cells may not be the ones that are most severely affected by this transactivation abnormality. For example, more dramatic effects may be seen in osteocytes for VDR transactivation and CNS glial cells for thyroid receptor transactivation as reported in TTD mice, 43 or in fetal cells during embryonic development. Each XPD mutation might affect the transactivation process differently. 25 The combination would be expected to lead to variability in nuclear receptor activity among different TTD and XP patients.
